TaiRx Biopharma is entering its "3.0" phase, characterized by triple-track growth: revenue expansion, accelerated R&D, and strategic partnerships. The company confirmed it will file for an IPO in the second half of this year.

• Core R&D (CVM-1118): TaiRx is launching a Phase 2 trial this quarter in China, combining CVM-1118 with Sintilimab (PD-1 antibody)—developed by Eli Lilly and Innovent Biologics—as a first-line treatment for intermediate-stage hepatocellular carcinoma (HCC). Enrollment is starting in 5–6 major centers across Shanghai, Beijing, and Fujian, with full data expected in H2 2027.
• Portfolio Expansion: Beyond liver cancer, TaiRx is collaborating with National Yang Ming Chiao Tung University for head and neck cancer research.
• Commercial Growth: Revenue grew 3.4-fold to NT$28 million last year. Its selenium deficiency injection, Zininte, has added Shinto Pharmaceutical as a partner to boost market penetration. An NDA for Zininte in China is planned for H2 2026.
• Strategy: The company is actively scouting for M&A and licensing opportunities to acquire innovative platforms and clinical-stage projects.

Resource: 台睿三軌並進推進下階段；下半年送件申請上市